Chemfab Alkalis Limited has announced its audited financial results for the quarter ended March 31, 2026, showcasing a sequential improvement in performance. The company recorded revenue from operations of 68.73 Crores in the current quarter, representing an 11.12% increase from 61.85 Crores in the previous quarter ended December 31, 2025. However, on a year-on-year (YoY) basis, revenue saw a decline of 21.76% compared to 87.85 Crores in the corresponding quarter of the previous year. In terms of profitability, the company achieved a Net Profit of 1.56 Crores, marking a significant turnaround from the Net Loss of 1.04 Crores reported in the preceding quarter. When compared to the 3.93 Crores profit in the same quarter last year, the net profit decreased by 60.31% YoY. The Board has also recommended a final dividend of Rs. 1.25 per share for the fiscal year 2025-26.

Chemfab Alkalis Limited is a pioneering chemical manufacturer that established India’s first membrane cell plant for Chloralkali production. The company’s core business includes the production of Caustic Soda, Liquid Chlorine, and Hydrogen Gas, alongside a strategic expansion into Oriented Poly Vinyl Chloride (OPVC) pipes. During 2025, the company successfully completed its Technology Modernisation Programme with the commissioning of a new plant on December 30, which is expected to drive significant operational efficiencies and cost savings. Additionally, the company made progress on its OPVC pipe division expansion at Sri City, receiving regulatory consent to enhance production capacity from 20 tonnes to 65 tonnes per day. The company’s shareholding remains concentrated, with promoters holding 72.13% of the total equity, including significant stakes held by prominent entities such as Dr. Rao Holdings Pte Ltd and individual promoter Suresh Krishnamurthi Rao.